Literature DB >> 1633525

Non-Hodgkin's lymphoma. I: Characterisation and treatment.

S E O'Reilly1, J M Connors.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1633525      PMCID： PMC1882392          DOI： 10.1136/bmj.304.6843.1682

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.

Authors:  M A Shipp; D P Harrington; M M Klatt; M S Jochelson; G S Pinkus; J L Marshall; D S Rosenthal; A T Skarin; G P Canellos
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

2.  Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.

Authors:  S Jagannath; W S Velasquez; S L Tucker; L M Fuller; P W McLaughlin; J T Manning; L B North; F C Cabanillas
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

3.  Non-Hodgkin's lymphomas. V. Results of radiotherapy.

Authors:  S E Jones; Z Fuks; H S Kaplan; S A Rosenberg
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

4.  Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.

Authors:  J K Luce; J F Gamble; H E Wilson; R W Monto; B L Isaacs; R L Palmer; C A Coltman; J S Hewlett; E A Gehan; E Frei
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

5.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

Authors:  P Klimo; J M Connors
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

6.  Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas.

Authors:  F Cabanillas
Journal:  Hematol Oncol       Date:  1985 Jan-Mar       Impact factor: 5.271

7.  Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.

Authors:  P J Hoskins; V Ng; J J Spinelli; P Klimo; J M Connors
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

8.  Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen.

Authors:  B Coiffier; E Lepage
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

9.  Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen.

Authors:  P McLaughlin; L M Fuller; W S Velasquez; J J Butler; F B Hagemeister; J A Sullivan-Halley; D O Dixon
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

10.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma.

Authors:  J M Connors; P Klimo; R N Fairey; N Voss
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391
View more
  6 in total

Review 1.  Non-Hodgkin's lymphoma. II: Management problems.

Authors:  S E O'Reilly; J M Connors
Journal:  BMJ       Date:  1992-07-04

2.  Primary small bowel non-Hodgkin's lymphoma with biliary and pancreatic duct obstruction.

Authors:  M Suri; A Sharma; H P Sachdev; R K Puri
Journal:  Indian J Pediatr       Date:  1994 Jan-Feb       Impact factor: 1.967

3.  Ophthalmoplegia as an unusual initial symptom of non-Hodgkins' lymphoma in the head and neck.

Authors:  A F Temmel; C Czerny; M Susani; M Kautzky
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.

Authors:  B Vaughan Hudson; G Vaughan Hudson; K A MacLennan; L Anderson; D C Linch
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

6.  Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.

Authors:  J H Youngson; J M Jones; J G Chang; M Harris; S S Banergee
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.